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Hypertrophic Cardiomyopathy and Dual Chamber
Pacing: Impact of Atrio-Ventricular Delay on
Obstruction Assessed by Doppler Echocardiography
Maria-Angela Losi, Sandro Betocchi, Carlo Briguori, Fiore Manganelli,
Giuseppe Stabile, Fabio Franculli, Carlo Pappone, Massimo Chiariello. Federico II
University, Naples, Italy
Obstruction in hypertrophic cardiomyopathy (HCM) benefits from atrio-
ventricular (AV) pacing with apical preexcitation To assess the impact of the
duration of AV delay on left ventricular outflow tract gradient (LVOTG), we
studied 8 patients with HCM and resting LVOTGs, implanted by permanent
AV pacemakers. LVOTG was measured by continuous Doppler echocardio-
graphy before implantation (B) and after, with the AV delay set at 120, 100,
and 80 ms: AV delay was randomly changed every day and LVOTG was mea-
sured after 24 hours. LVOTG decreased significantly with shorter AV delays
(Figure). All patients had significant LVOTGs (i.e >30 mmHg) at B, 6 at AV
delay of 120 ms, 3 at AV delay of 100 ms, and 4 at AV delay of 80 ms (p <
005 at X 2 for the group); moreover, the incidence of significant LVOTG was
significantly less with AV delays of 100 (p < 0.Q1) and 80 ms (p < 0.05) than
in B. Furthermore, minimum LVOTG was obtained with AV delay of 100 and
80 ms in 4 patients each.
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Conclusions: 1) AV pacing reduces LVOTG in HCM; 2) the decrease in
LVOTG is greater with shorter AV delays; 3) significant LVOTGs are abolished
by short AV delays; 4) optimal AV delay seems to be between 80 and 100
ms.
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J756i] Effect of Long-term ACE-inhibitor Therapy in
Hypertrophic Cardiomyopathy (HCM)
Andreas Hartmann, Angela POtz, ROdiger Hopf. Dept of Cardiology, University
Medical Center, and Division of Internal Medicine, Krankenhaus Sachsenhausen,
Frankfurt Germany
ACE-inhibitors (ACI) reduce left ventricular hypertrophy in patients with
hypertension. There is experimental evidence that ACI may reduce non-
hypertensive left ventricular hypertrophy. It was the goal of this study to
investigate the effect of ACI therapy on left ventricular dimensions and exer-
cise capacity in patients with HCM, 26 patients (P) with HCM were divided
in two groups matched for age, sex and severity of disease. 13 P (group I: 2
f, 11 m, age 59 ± 3.7 years) were treated with Ca-channel or beta-blockers.
13 P (group II: 2 f, 11 m, age 62 ± 2.6 years) were additionally treated 'with
ACI (captopril 37,5 mg/d, enalapril 5-10 mg/d). M-mode, 2-D and Doppler
echocardiography as well as exercise tests were performed at the begin-
ning (BEGIN) and at the end (END) of the observation period (group' 43 ±
3 months, group II: 44 ± 7 months). Septum and left ventricular posterior
wall thickness (SEP, LVPW - mm), left atrial and left ventricular end diastolic
diameter (LA, EDD - mml, intraventricular gradient (GRAD - mmHgl, duration
(DUR - min,) and level (WATT-watt) of exercise were documented (Mean ±
SEM),
SEP LVP'N LA EDD GRAD DUR WAIT
Group I:
BEGIN 20 ± 1.3 13 ± 0.6 46 ± 2,6 47 ± 1,7 32 ± 5 5±04 98 ± 9
END 18 ± 1.3 12 ± 07 47 ± 27 47 ± 2.7 42 ± 12 5 ± 0.3 94 ± 8
Group 1/:
BEGIN: 19 ± 1.6 13± 1,0 45 ± 20 50 ± 1.7 20 ± 6 5 ± 0.5 96 ± 9
END 17 ± 1.8 11 ± 0,5 47 ± 1,B 50 ± 2.0 23 ± 9 5 ± 0.5 98 ± 9
Conclusion: There were no significant differences in left ventricular dimen-
sions and exercise capacity between treated and untreated patients, In con-
trast to hypertensive left ventricular hypertrophy, non-hypertensive hyper-
trophic cardiomyopathy is not reduced by ACI.
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1757-1 I The Effect of Vasopressin V1 and V2 Receptor
Antagonists on Heart Failure After Myocardial
Infarction
Hisayoshi Fujita, Minoru Yoshiyama, Hiroyuki Yamagishi, Akihisa Hanatani,
Iku Toda, Kaname Akioka, Masakazu Teragaki, Kazuhide Takeuchi, Hiroshi Iwao 1,
Tadanao Takeda. First Department of Internal Medicine, Osaka City, University Medical
School, Osaka, Japan: 1 Department of Pharmacology, Osaka City, University Medical
School, Osaka, Japan
Arginine vasopressin may contribute to cardiovascular regulation by causing
vasoconstriction and stimulating renal water absorption through V1 and V2
receptors, respectively. Arginine vasopressin may play an important role in
congestive heart failure. Recently, oral vasopressin V1 and V2 receptor an-
tagonists were synthesized, however, the effect of vasopressin V1 and V2
receptor antagonists on heart failure is still unclear, We examined the effect
of vasopressin Vl receptor antagonist and vasopressin V2 receptor antago-
nist on heart failure after acute and chronic myocardial infarction. Myocardial
infarction was made to the rats by ligation of left anterior descending coro-
nary artery, On one day (acute) and two months (chronic) after the surgery,
we orally administered V1 receptor antagonist at 60 mglkg/day or V2 recep-
tor antagonist at 30 mg/kg/day to myocardial infarcted rats. After one week
of treatment. we measured the hemodynamics and electrolytes in the blood.
In the acute and chronic myocardial infarcted rats, the left ventricular endo-
diastolic pressure (LVEDP) increased to 16 ± 3 and 20 ± 4 mmHg, respec-
tively, and V2-ant decreased LVEDP to 6 ± 41p < 0,01) and 5 ± 3 mmHg (p
< 0.011, respectively. V2-ant decreased significantly the left ventricular endo-
diastolic volume (LVEDV) in chronic myocardial infarction (non-treated rats;
2.31 ± 0.18, V2-ant treated vats; 1,76 ± 0.10 mllkgl(p < 0,01). In the chronic
myocardial infarcted rats, abdominal ascites appeared, and the weight of
lung or liver increased, V2 receptor antagonist decreased them. V2 receptor
antagonist improved hemodynamics and the signs of heart failure in myocar-
dial infarcted rats. V1 receptor antagonist tended to decrease LVEDP in the
acute and chronic myocardial infarcted rats. V1 and V2 receptor antagonists
did not change the electrolytes in the blood, Vasopressin antagonist, espe-
ciallyV2 receptor antagonist, is a useful drug for heart failure after myocardial
infarction.
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1757-21 Angiotensin II Formation in the Intact Human Heart:
Predominance of the Angiotensin Converting
Enzyme Pathway
Lawrence S. Zisman, William 1. Abraham, Glenn E. Meixell, Brian N. Vamvakias,
Brian D. Lowes, Robert L. Roden, Robert A. Quaife, Bertron M. Groves, M.
Benjamin Perryman, Michael R. Bristow. University of Colorado Health Sciences
Center, Denver, Colorado
It has been proposed that the contribution of myocardial tissue angiotensin
converting enzyme (ACE) to angiotensin II (Ang II) formation in the heart is
low compared to non-ACE pathways. However, little is known about the ac-
tual in vivo contribution of these pathways to Ang II formation in the human
heart, Accordingly, we developed a method to quantify ACE and non-ACE-
mediated conversion of angiotensin I (Ang I) to Ang II across the myocardial
circulation in human subjects. Using an intracoronary(lC) infusion of 1231_Ang
I before and during an IC infusion of enalaprilat, we measured the fractional
conversion of Ang I to Ang II in coronary sinus blood samples by taking the
ratio of the labeled Ang II activity to the sum of activity corresponding to
labeled Ang I and Ang II after peptide extraction and separation by HPLC
(activity ratio method). Results obtained from this method were confirmed
by combined HPLC/RIA of both labeled and unlabeled Ang I and Ang II (RIA
method), The initial experience has been obtained in orthotopic heart trans-
plant recipients with normal cardiac function and coronary anatomy,
After a six minute IC infusion of 1231_Ang I, fractional conversion of Ang I
to Ang II was 0.44 ± 0.141, and 0.43 ± 0.084 (n = 4, mean ± SD) as deter-
mined, respectively, by the activity ratio and RIA methods. IC enalaprilat (0,01
mg/min for five minutes) reduced fractional conversion to 0.046 ± 0,065 (ac-
tivity ratio method) or 0.033 ± 0.012 (RIA method) In = 3, P = 0,014).
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Conclusions: 1) Ang II formation can be measured in the intact human
heart; 21 ACE mediates 90% of Ang I to Ang II conversion across the my-
ocardial circulation.
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phosphodiesterases (POE), we assessed a role for altered cGMp·POE activity
(pmollmln/mg) In the blunted renal ANP response in HF, Isolated glomeruli
and inner medullary collecting duct cells (IMCO) from kidneys of mongrel
dogs 8 days follOWing TIVCC (n = 4) were compared to control animals (n
= 6). Total cGMP-POE activity in the presence of 10 I'M calcium (Ca) and
10 JLg/ml calmodulin (CaM) was significantly higher in glomeruli from TIVCC
(657 ±81 vs. control 361 ± 31, P <:: 0.05) but not in 1MCD (2693± 794vs. con-
trol3371 ± 370, p = NS). From POE isozymes hydrolyzing cGMP in glomeruli,
POE-V activity (defined as cGMP-POE in the absence of Ca/CAM) was higher
in glomeruli from TIVCC (342 ± 72 vs. control: 154 ± 14, p <:: 0.05). while
POE-I activity (defined as total cGMP-POE minus POE-V) and total adenosine
3',5'-cyclic monophosphate (cAMP) POE activity were not significantly differ-
ent in glomerUli and IMCO from TIVCC and control dogs.
In order to test the physiological significance, zaprinast, a specific POE-V
inhibitor was infused intrarenally (5 JLg!kg!min) in TIVCC dogs (n = 6) and
compared to vehicle, ANP (100 ng!kg/min Lv.) in combination with zaprinast
showed a significantly higher urinary sodium excretion (104 ± 34 vs. ANP
alone: 69 ± 26 JLEq/min, p < 0.05) in association with increases in glomerular
filtratIOn rate (43 ± 7 vs. 31 ± 4 mllmin, p < 0.05).
. We conclude that cGMP-POE activity is upregulated in glomeruli in exper-
Imental heart failure. This increased activity in a known target site of ANP
action may represent a cellular mechanism of ANP resistance in heart fail-
ure by inactivating cGMP produced in response to ANP. Targeted pharmaco-
logical intervention via phosphodiesterase inhibition may improve the ANP
response in heart failure in vivo.
*p < 0.05 vS CONTROL. +p < 0.05 vs DCM
In the next set of experiments, Na+ ,K+-ATPase binding density (Bmax).
affinity (Kd), and ATPase activity (ACT) were computed from sarcolemmal
preparations. AT1 AT-II receptor blockade normalized Na+ ,K+-ATPase density
and Increased hydrolytic capacity. HR MAP PAP PCWP CI
Before Placebo 72 ± 9 Bl ± 8 36 ± 8 23 ± 5 2.3 ± 0.3
Peak Placebo 83 ± 12 75 ± 7 35 ± 8 21 ±6 23 ± 0,3
Before BNP 72± 11 85 ± 10 38± 7 25 ± 5 2.1 ± 0.3
Peak BNP 88± 20 68 ± 9* 22 ± 7* 10 ± 5* 2,7 ± 0.5t
3:00
Hemodynamic Effects of Synthetic Human Brain
Natriuretic Peptide Infusion in Patients with Severe
Congestive Heart Failure: A Placebo-controlled,
Crossover Trial
Lee S. Marcus, Douglas Hart, Milton Packer, Madeline Yushak, Norma Medina,
Stuart D. Katz. Columbia University Col/ege of Physicians and Surgeons, New York, NY
Brain natriuretic peptide IBNP) and atrial natriuretic peptide (ANP) are
naturally-occurring peptide hormones with vasodilating and natriuretic prop-
erties, Although the two peptides are structurally similar, the primary site of
synthesis" receptor binding properties and metabolic clearance pathways of
BNP are distinct from those of AN P. While the plasma concentrations of both
BNP and ANP are increased in patients with congestive heart failure (CHF),
the biologic significance of this increase is uncertain since the vasodilatory
effects of exogenous ANP are attenuated in patients with CHF. To determine
if the vasodilating effects of BNP are similarly attenuated in patients with
CHF, the acute hemodynamic effects of exogenous synthetic human BNP in-
fusion (Scios Nova) were determined in 10 patients with chronic NYHA Class
III congestive heart failure (mean age 55 yrs, mean LVEF 21 %) in a double-
blind, placebo-controlled crossover trial. BNP or matching placebo solutions
were administered intravenously in 4 incremental doses ranging 0.003-0.1
JLg!kgfmin over 6 hours on two consecutive days. Heart rate (HRl. mean arte-
rial pressure (MAPl. mean pulmonary artery pressure (PAP). pulmonary cap-
illary wedge pressure (PCWP) and cardiac index (CI) were measured before
study drug administration on each day and 60 and 90 minutes after each
upward dose increment. Hemodynamic measurements before drug admin-
istration and peak hemodynamic responses to administration of human BNP
and placebo were as follows:
MYOVEL
57 ± 1
36± 1*
41 ± 1*
ACT (JLg/mglhr)
056 ± 009
0.37 ± 009*
0.96 ± 0.23*+
AP090
226 ± 8
257 ± 9*
183± 14*+
Kd (nM)
25.3 ± 15
19.9 ± 1.8*
22.7 ± 2.8
-78 ± 1 15B ± 9
-71 ± 1* 121 ± 5*
-76 ± 1+ 165 ± 13+
RMP VmaxLVEDV
69 ± 4
101 ± 7*
93 ± 6*
Bmax (pmol/mg)
3.2 ± 0.3
1.9 ± 0.3*
2.7 ± 0.2+
LVEF
73 ± 2
35 ± 3*
35 ± 2*
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Chronic Angiotensin II Receptor Blockade (AT1 AT-II)
Affects Myocyte Sarcolemmal Function and
Electrophysiology in Dilated Cardiomyopathy
Francis G. Spinale. R. Barry Hird, Rupak Mukherjee, Jennifer D. Walker, Henry
H. Holzgrefe, Michael J. Child, William H. Koster. Med Univ of South Carolina Chas
SC: Bristol Myers Squibb Research /nsMute, Princeton, NJ ' ,
CONTROL
OCM
OCM/AT-BLOCK
We tested the hypothesis that AT, AT-II receptor activation with the pro-
gression of dilated cardiomyopathy (OCMI causes fundamental changes
In myocyte (MYO) sarcolemmal processes. Six dogs were assigned to
each of 3 groups: (1) DCM: tachycardia induced OCM (pace 216;4
wks). (2) DCM/AT-BLOCK; chronic pace and concomitant treatment with
a specific non-peptide ATl AT-II antagonist (BMS 186295; 30 mg/kg
BIOI (3) CONTROL. LV ejection fraction (LVEFOfoI and end-diastolic volume
(LVEOV;cc) were measured by echo/cath. Simultaneous indices of MYO
membrane potential (resting;RMP;mV, upstroke velocity;Vmax;V/s, time
to 90% repolarization;AP090 ;ms) and contraction (velocity of shortening;
MYOVEL;JLm!sl were measured by videomicroscopy and microelectrodes.
CONTROL
OCM
OCM/AT-BLOCK
Summary: Concomitant AT, AT-II receptor blockade during the develop-
ment of OCM normalized MYO membrane potentials. A fundamental mech-
anism for these effects were preserved sarcolemmal Na+ ,K+ -ATPase density
and enhanced activity.
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1757-41 Differential Regulation of Renal Cyclic Nucleotide
Phosphodiesterases in Experimental Heart Failure
Roland R. Brandt, Holger Heinrich, Claudia C.S. Chini, Lawrence L. Aarhus,
Thomas P. Dousa, John C. Burnett, Jr.. Mayo Clinic and Foundation, Rochester, MN
Thoracic inferior vena caval constriction (TIVCC) is a model of experimen-
tallow cardiac output heart failure (HF) that results in sodium retention and
a blunted natriuretic response to atrial natriuretic peptide (ANP). Recogniz-
Ing that the biological actions of ANP are mediated through guanosine-3',5'-
cyclic monophosphate (cGMP) which is metabolized by multiple isozymes of
* indicates p < 0.01 versus peak placebo; t indicates p = 0.055 versus peak placebo
Two patients did not tolerate the highest dose of BNP because of transient
symptomatic hypotension. In conclusion, short-term intravenous infusion of
human BNP acutely improves hemodynamic function in patients with ad-
vanced CHF. These findings contrast with previous studies demonstrating
attenuated acute hemodynamic effects of exogenous ANP and suggest that
the physiologic and pharmacologic roles of these two natriuretic peptide
hormones may differ.
